Dr. Geoff Houlton was the CEO and a Director of Heart Force Medical. He enabled the financing and development of a nascent medical technology based on algorithmic analysis of sub-audible frequencies emanating through the chest from the heart. Under his leadership, the company registered two products; an initial product registered with Health Canada, the FDA and the European Regulatory Agency and a second certified by Health Canada.
Previously, Geoff worked as a Health Sciences Analyst for a number of Canadian investment banks including: Octagon Capital, Loewen Ondaatje McCutcheon and Union Securities Capital Markets Group. He was also a Founding Partner, Director, Vice President and Chief Scientific Officer of BioCatalyst Yorkton Inc., a venture management company which sourced early stage technologies and created the corporate entity to develop these into products for acquisition.
His introduction to venture capital was with MDS Health Sciences, where one of his roles was to assess new technologies for potential investment. As one of the Entrepreneurs in Residence he was also seconded to individual companies to assist in managing product development and complementing corporate financing processes to enable successful financing of investments.
Prior to this, Geoff led the development of the Medical Affairs Department of Glaxo Canada Inc. now Glaxo SmithKline (GSK), and was medical advisor in product development for the pharmaceutical industry in the UK.
Geoff qualified in medicine from Ninewells Medical School at the University of Dundee and completed residency training in anesthesiology.